

Pages 1-5 redacted under section 22(1) of the FOI Act (irrelevant information)



61

SmithKline Beecham
Pharmaceuticals

27 August 1993

[REDACTED]
Academic Unit of Acute Psychiatry
NEMPS
PO Box 101
BUNDOORA VIC 3083

Dear [REDACTED]

Re: Paroxetine/Fluoxetine Clinical Trial (#356) - Suicide Attempts

As we have now received reports of 7 suicide attempts (including 2 deaths) for the (356) study comparing paroxetine and fluoxetine I am writing to all Investigators to provide you with further information and to reinforce SmithKline Beecham's viewpoint that they are unlikely to be causally related to paroxetine (or indeed fluoxetine). I understand that details of the cases have already been presented to you in the Study Newsletter which [REDACTED] distributes, however you may wish to submit the attached information to your IEC as well. We would, however, request a copy of your letter and their response for our files.

[REDACTED]

[REDACTED]

